The William Acquavella Heart Valve Center at NewYork-Presbyterian/Weill Cornell is dedicated to developing and evaluating new and less-invasive techniques for repairing and replacing damaged mitral, aortic, and pulmonary valves. The Center's team of experts has played a leading role in clinical trials assessing the latest percutaneous valve replacement approaches, giving it greater experience than most centers in these emerging new techniques.
One of the most promising procedures for select patients with severe symptomatic aortic stenosis (narrowing of the aortic valve opening) is Transcatheter Aortic Valve Replacement (TAVR). This most common form of valvular heart disease affects up to 1.5 million people in the United States. As we age, our heart valves become stiff or weak and if this becomes severe enough, it will reduce the valve’s ability to open and close completely. Thus, less oxygen-rich blood is pumped out to the body and may cause such symptoms as shortness of breath, fainting, heart palpitation.
TAVR allows doctors to implant a device into a heart valve without open surgery.
Our Cardiologist, together with our partners in the Department of Cardiothoracic Surgery, were investigators of the national clinical trials establishing the effectiveness of Transcatheter Aortic Valve Replacement (TAVR). TAVR is an FDA approved treatment and is covered by Medicare and most major insurances. For video simulations of the TAVR procedure produced by the manufacture Edwards of the SAPIEN valve, you can visit their website at: http://www.edwards.com/products/transcathetervalve/Pages/THVcategory.aspx
PARTNER Trial – NewYork- Presbyterian
This transformative technique has made valve replacement possible for many patients who cannot tolerate conventional heart surgery, and who otherwise, would not have had any other treatment options.
To refer a patient or to make an appointment with a specialist at our Center:
Phone: 646-NYP-VALVE (646-697-8258)